International Journal of Coronaviruses

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

Dr. Mohammad Meshkini, Associate Professor at Tabriz University, expert in Cancer Cell Signaling.

Iran, Islamic Republic of

Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

Send an Email

Dr. Mohammad Meshkini

Address:

Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences

Daneshgah St., Tabriz, East Azerbaijan Province, Iran


Academic Metrics
  • h-index: 6
  • i10-index: 4
  • Total Citations: 121

Research Interests:

  • Molecular Oncology
  • Cancer Cell Signaling (PI3K/AKT/mTOR, Wnt)
  • Hepatocellular Carcinoma (Liver Cancer)
  • Breast Cancer
  • Apoptosis and Cell Proliferation
  • Molecular Mechanisms of Cancer
  • Cancer Drug Discovery
  • Gene Expression Regulation

Biography:

Dr. Mohammad Meshkini is a dedicated researcher and Associate Professor in the Department of Molecular Medicine at Tabriz University of Medical Sciences. His research is centered on elucidating the complex molecular mechanisms that drive cancer development, with a particular emphasis on hepatocellular carcinoma (liver cancer). Dr. Meshkini investigates key cellular signaling pathways, such as PI3K/AKT/mTOR, and their role in cancer cell proliferation, apoptosis, and metastasis. He also explores the potential of various natural and synthetic compounds as therapeutic agents to target these pathways and inhibit cancer growth. His work combines molecular biology, cell culture, and animal models to translate fundamental discoveries into potential clinical applications. Dr. Meshkini has a strong publication record and is actively involved in mentoring graduate students, contributing to the advancement of cancer research.


Education Details:
  • PhD in Molecular Medicine, Tarbiat Modares University, Tehran, Iran (2014)
  • MSc in Clinical Biochemistry, Tabriz University of Medical Sciences, Tabriz, Iran (2007)
  • BSc in Laboratory Sciences, Tabriz University of Medical Sciences, Tabriz, Iran (2004)

Professional Background:
  • Associate Professor, Department of Molecular Medicine, Tabriz University of Medical Sciences, Iran (Present)
  • Head of Department, Department of Molecular Medicine, Tabriz University of Medical Sciences, Iran

Achievements:
  • Recipient of various institutional and national research grants for work on cancer signaling pathways.
  • Serves as Head of the Department of Molecular Medicine at the Faculty of Advanced Medical Sciences.

Current Research Projects 

His current research focuses on the crosstalk between major signaling pathways (e.g., Wnt/β-catenin and PI3K/AKT) in liver cancer and their role in chemoresistance. He is also actively evaluating the anticancer effects of specific microRNAs and novel drug formulations, including nanoliposomal delivery systems for natural compounds.


Academic Profiles of Dr. Mohammad Meshkini

Publications:

Dr. Meshkini has a strong publication record in journals focused on molecular medicine and cancer research. His recent work investigates the effects of various compounds on critical cancer signaling pathways, providing valuable insights for developing novel therapeutic strategies.

List of Recent Publications:

  • Jalili, A., Aghamohammadi, A., Meshkini, M., & Ghorbani, M. (2025). Nanoliposomal formulation of Gallic acid induces apoptosis and inhibits cell cycle in HepG2 cancer cells via PI3K/Akt signaling pathway. Journal of Drug Delivery Science and Technology, 91, 106037. DOI: https://doi.org/10.1016/j.jddst.2024.106037
  • Taghizadeh, S., Meshkini, M., & Ghorbani, M. (2024). The effect of nanoliposomal curcumin on the expression of long non-coding RNA H19 and cell death in the HepG2 cell line. Molecular Biology Research Communications, 13(2), 79-87. DOI: https://doi.org/10.22099/mbrc.2024.51261.1824
  • Sadigh, A. R., Aghamohammadi, A., Meshkini, M., & Ghorbani, M. (2024). Nanoliposomal formulation of caffeic acid phenethyl ester inhibits proliferation and promotes apoptosis in HepG2 cells via PI3K/Akt pathway. Research in Pharmaceutical Sciences, 19(2), 169-180. DOI: https://doi.org/10.4103/1735-5362.395431
  • Ghorbani, M., Meshkini, M., & Jalili, A. (2023). Synergistic effect of doxorubicin and caffeic acid phenethyl ester on apoptosis and cell cycle in hepatocarcinoma cell line. Advanced Pharmaceutical Bulletin, 13(4), 792-800. DOI: https://doi.org/10.34172/apb.2023.084
  • Fathi, E., Sanaat, Z., Meshkini, M., & Farahzadi, R. (2023). The effect of exosomes derived from mesenchymal stem cells on acute lymphoblastic leukemia cells. Cell and Tissue Research, 394(2), 335-346. DOI: https://doi.org/10.1007/s00441-023-03815-5



Last Updated on October 12, 2025